PerkinElmer Inc. has unveiled new solutions to improve speed and effectiveness of life sciences research processes. These solutions assist scientists in drug discovery, cellular research, biotherapeutics, genetics, genomics and protein research. These technologies allow researchers to automate and improve the efficiency of their workflows across liquid handling, assays, big data and informatics processing, high content imaging and nucleic acid extraction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103 USD | -1.77% |
|
-3.65% | -5.77% |
06-27 | Barclays Trims Price Target on Revvity to $115 From $116 | MT |
06-20 | Bionano Genomics Says Revvity to Commercialize VIA Software | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.77% | 12.71B | |
+2.06% | 207B | |
+5.69% | 181B | |
+29.31% | 155B | |
+2.36% | 64.42B | |
+18.36% | 54.38B | |
-1.92% | 47.43B | |
-8.37% | 37.17B | |
-1.37% | 34.81B | |
+8.67% | 27.46B |
- Stock Market
- Equities
- RVTY Stock
- News Revvity, Inc.
- PerkinElmer Unveils New Solutions for Life Sciences Research Processes